Budesonide for maintenance of remission in Crohn's disease (Q24194313)

8

0 references

A Hillary Steinhart

5

object named as

A Hillary Steinhart

0 references

author name string

Ali Rezaie

2

0 references

Cynthia H Seow

3

0 references

Anthony R Otley

4

0 references

Anne Marie Griffiths

6

0 references

Gilaad G Kaplan

Cochrane Database of Systematic Reviews

7

0 references

publication date

21 August 2014

0 references

published in

0 references

cites work

Switch from systemic steroids to budesonide in steroid dependent patients with inactive Crohn's disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002913.PUB3

Oral budesonide as maintenance therapy in Crohn's disease--results of a 12-month study. Global Budesonide Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002913.PUB3

Low dose oral pH modified release budesonide for maintenance of steroid induced remission in Crohn's disease. The Budesonide Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002913.PUB3

Budesonide as maintenance treatment in Crohn's disease: a placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002913.PUB3

Budesonide prolongs time to relapse in ileal and ileocaecal Crohn's disease. A placebo controlled one year study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002913.PUB3

Budesonide versus mesalamine for maintaining remission in patients refusing other immunomodulators for steroid-dependent Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002913.PUB3

Azathioprine is superior to budesonide in achieving and maintaining mucosal healing and histologic remission in steroid-dependent Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002913.PUB3

Bone mineral density in relation to efficacy and side effects of budesonide and prednisolone in Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002913.PUB3

Oral budesonide significantly improves water absorption in patients with ileostomy for Crohn disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002913.PUB3

Maintenance of Crohn's disease over 12 months: fixed versus flexible dosing regimen using budesonide controlled ileal release capsules

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002913.PUB3

Comparison of two dosing methods for induction of response and remission with oral budesonide in active pediatric Crohn's disease: a randomized placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002913.PUB3

Budesonide for maintenance of remission in patients with Crohn's disease in medically induced remission: a predetermined pooled analysis of four randomized, double-blind, placebo-controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002913.PUB3

Efficacy and tolerability of oral budesonide in Japanese patients with active Crohn's disease: a multicentre, double-blind, randomized, parallel-group Phase II study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002913.PUB3

Budesonide 9 mg is at least as effective as mesalamine 4.5 g in patients with mildly to moderately active Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002913.PUB3

Anti-inflammatory actions of steroids: molecular mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002913.PUB3

Inflammatory bowel disease: clinical aspects and established and evolving therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002913.PUB3

Differentiating ulcerative colitis from Crohn disease in children and young adults: report of a working group of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition and the Crohn's and Colitis Foundation of America

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002913.PUB3

Bone mineral density in Crohn's disease: a longitudinal study of budesonide, prednisone, and nonsteroid therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002913.PUB3

Meta-analysis in clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002913.PUB3

Assessing the Quality of Randomised Controlled Trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002913.PUB3

Targeted delivery, safety, and efficacy of oral enteric-coated formulations of budesonide

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002913.PUB3

GRADE: an emerging consensus on rating quality of evidence and strength of recommendations

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002913.PUB3

A simple index of Crohn's-disease activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002913.PUB3

Measuring inconsistency in meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002913.PUB3

Development and validation of an endoscopic index of the severity for Crohn's disease: a prospective multicentre study. Groupe d'Etudes Thérapeutiques des Affections Inflammatoires du Tube Digestif (GETAID)

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002913.PUB3

IBD across the age spectrum: is it the same disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002913.PUB3

Design issues and outcomes in IBD clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002913.PUB3

Budesonide for induction of remission in Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002913.PUB3

A meta-analysis of the placebo rates of remission and response in clinical trials of active ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002913.PUB3

High levels of glucocorticoid receptors in patients with active Crohn's disease may predict steroid resistance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002913.PUB3

Treating Crohn's disease by inducing T lymphocyte apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002913.PUB3

An index of inflammatory activity in patients with Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002913.PUB3

Corticosteroids in Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002913.PUB3

Budesonide for maintenance of remission in Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002913.PUB3

Budesonide for maintenance of remission in Crohn's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002913.PUB3

Maintenance treatment with budesonide 6 mg versus 9 mg once daily in patients with Crohn's disease in remission

21 January 2018

1 reference

12 December 2020

Predictability of the postoperative course of Crohn's disease

1 reference

12 December 2020

Low-dose budesonide treatment for prevention of postoperative recurrence of Crohn's disease: a multicentre randomized placebo-controlled trial. German Budesonide Study Group

1 reference

12 December 2020

Immunosuppressant Medications and Mortality in Inflammatory Bowel Disease

1 reference

12 December 2020

Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study

1 reference

12 December 2020

Corticosteroids in the treatment of gastrointestinal disease

1 reference

12 December 2020

Oral budesonide as maintenance treatment for Crohn's disease: a placebo-controlled, dose-ranging study. Canadian Inflammatory Bowel Disease Study Group

1 reference

12 December 2020

Inflammatory bowel disease

1 reference

12 December 2020

Oral budesonide for prevention of postsurgical recurrence in Crohn's disease. The IOIBD Budesonide Study Group

1 reference

12 December 2020

European Cooperative Crohn's Disease Study (ECCDS): results of drug treatment

1 reference

12 December 2020

Development and validation of a pediatric Crohn's disease activity index

1 reference

12 December 2020

Early lesions of recurrent Crohn's disease caused by infusion of intestinal contents in excluded ileum

1 reference

12 December 2020